FOSTER CITY, Calif., February 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated for parallel accelerated review the company’s ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback